{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:11:12Z","timestamp":1794463872711,"version":"4.9.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This double-blind study (ASPIRE II) randomized adults (aged 18\u201364 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization \u22655 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression\u2013Severity of Suicidality\u2013revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy\/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: \u201315.7 [11.56]) vs placebo (\u201312.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: \u20133.9 [1.39], 95% CI: \u20136.60, \u20131.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference \u20134.2, 95% CI: \u20136.38, \u20131.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression\u2013Severity of Suicidality\u2013revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent.<\/jats:p>\n                    <jats:p>Trial Registration: Clinical Trials.gov identifier: NCT03097133<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa068","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T15:13:34Z","timestamp":1598454814000},"page":"22-31","source":"Crossref","is-referenced-by-count":249,"title":["Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)"],"prefix":"10.1093","volume":"24","author":[{"given":"Dawn F","family":"Ionescu","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Statistics, Janssen Research and Development, LLC, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Statistics, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Statistics, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[{"name":"Center of Brain Research, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C","family":"Drevets","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husseini","family":"Manji","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M","family":"Canuso","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Janssen Research and Development, LLC, Titusville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"2021012009030678200_CIT0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113495","article-title":"Suicide ideation and behavior assessment tool (SIBAT): evaluation of intra- and inter-rater reliability, validity, and mapping to Columbia Classification Algorithm of Suicide Assessment","author":"Alphs","year":"2020"},{"issue":"11","key":"2021012009030678200_CIT0002","first-page":"1","article-title":"Practice guideline for the assessment and treatment of patients with suicidal behaviors","volume":"160","author":"American Psychiatric Association","year":"2003","journal-title":"Am J Psychiatry"},{"key":"2021012009030678200_CIT0003","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5) 5th ed","author":"American Psychiatric Association","year":"2013"},{"key":"2021012009030678200_CIT0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0165-0327(99)00004-X","article-title":"Lifetime suicide risk in major depression: sex and age determinants","volume":"55","author":"Blair-West","year":"1999","journal-title":"J Affect Disord"},{"key":"2021012009030678200_CIT0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1024465317902","article-title":"Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)","volume":"11","author":"Bremner","year":"1998","journal-title":"J Trauma Stress"},{"key":"2021012009030678200_CIT0006","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1037\/0022-006X.68.3.371","article-title":"Risk factors for suicide in psychiatric outpatients: a 20-year prospective study","volume":"68","author":"Brown","year":"2000","journal-title":"J Consult Clin Psychol"},{"key":"2021012009030678200_CIT0007","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2021012009030678200_CIT0008","doi-asserted-by":"crossref","first-page":"112810","DOI":"10.1016\/j.psychres.2020.112810","article-title":"Frequency of rehospitalization after hospitalization for suicidal ideation or suicidal behavior in patients with depression","volume":"285","author":"Cepeda","year":"2020","journal-title":"Psychiatry Res"},{"key":"2021012009030678200_CIT0009","first-page":"244","article-title":"Validity and reliability of the observer\u2019s assessment of alertness\/sedation scale: study with intravenous midazolam","volume":"10","author":"Chernik","year":"1990","journal-title":"J Clin Psychopharmacol"},{"key":"2021012009030678200_CIT0010","doi-asserted-by":"crossref","first-page":"e023883","DOI":"10.1136\/bmjopen-2018-023883","article-title":"Meta-analysis of suicide rates in the first week and the first month after psychiatric hospitalisation","volume":"9","author":"Chung","year":"2019","journal-title":"BMJ Open"},{"key":"2021012009030678200_CIT0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD)","volume":"21","author":"Dold","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021012009030678200_CIT0012","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"2021012009030678200_CIT0013","doi-asserted-by":"crossref","first-page":"19m13191","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depression symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2021012009030678200_CIT0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1521\/suli.2008.38.5.539","article-title":"The emergence of suicidal ideation during the post-hospital treatment of depressed patients","volume":"38","author":"Gaudiano","year":"2008","journal-title":"Suicide Life Threat Behav"},{"key":"2021012009030678200_CIT0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fpsyt.2016.00109","article-title":"Clinical characteristics associated with suicide attempts in clinical settings: a comparison of suicidal and non-suicidal depressed inpatients","volume":"7","author":"Gramaglia","year":"2016","journal-title":"Front Psychiatry"},{"key":"2021012009030678200_CIT0016","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","article-title":"Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States","volume":"75","author":"Hasin","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2021012009030678200_CIT0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1176\/appi.ajp.2010.09050627","article-title":"Incidence and predictors of suicide attempts in DSM-IV major depressive disorder: a five-year prospective study","volume":"167","author":"Holma","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2021012009030678200_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"key":"2021012009030678200_CIT0019","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1192\/bjp.bp.113.140343","article-title":"Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression","volume":"205","author":"Leuchter","year":"2014","journal-title":"Br J Psychiatry"},{"key":"2021012009030678200_CIT0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/da.22473","article-title":"Suicidal depressed patients respond less well to antidepressants in the short term","volume":"33","author":"Lopez-Castroman","year":"2016","journal-title":"Depress Anxiety"},{"key":"2021012009030678200_CIT0021","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2021012009030678200_CIT0022","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1176\/ajp.2007.164.7.1029","article-title":"Suicide attempts among patients starting depression treatment with medications or psychotherapy","volume":"164","author":"Simon","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2021012009030678200_CIT0023","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.4088\/JCP.v64n0916","article-title":"Suicidal ideation and attempts among psychiatric patients with major depressive disorder","volume":"64","author":"Sokero","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"2021012009030678200_CIT0024"},{"key":"2021012009030678200_CIT0025","volume-title":"Spravato (esketamine) nasal spray. Prescribing information"},{"key":"2021012009030678200_CIT0026","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jad.2018.10.108","article-title":"Comparing factor structures of depressed patients with and without suicidal ideation, a measurement invariance analysis","volume":"245","author":"van Ballegooijen","year":"2019","journal-title":"J Affect Disord"},{"key":"2021012009030678200_CIT0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1027\/0227-5910\/a000109","article-title":"Best practice elements of multilevel suicide prevention strategies: a review of systematic reviews","volume":"32","author":"van der Feltz-Cornelis","year":"2011","journal-title":"Crisis"},{"key":"2021012009030678200_CIT0028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eurpsy.2011.06.003","article-title":"The European Psychiatric Association (EPA) guidance on suicide treatment and prevention","volume":"27","author":"Wasserman","year":"2012","journal-title":"Eur Psychiatry"},{"key":"2021012009030678200_CIT0029","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1192\/bjp.bp.106.032532","article-title":"Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA)","volume":"192","author":"Williams","year":"2008","journal-title":"Br J Psychiatry"},{"key":"2021012009030678200_CIT0030","author":"World Health Organization","year":"2019"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa068\/33877193\/pyaa068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/1\/22\/35927276\/pyaa068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/1\/22\/35927276\/pyaa068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T08:44:39Z","timestamp":1617007479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/24\/1\/22\/5899217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa068","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,8,29]]}}}